Asia-Pacific dry powdered inhaler market is anticipated to grow at a substantial rate of around 4.0% during the forecast period. Major factors that augments the growth of the market include large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and significant presence of market players in the region. Asia-Pacific has a potential market due to the increasing R&D and investments by big pharmaceutical companies in life science research coupled with harnessing innovation. The dry powdered inhaler market in the Asia-Pacific region presents future opportunities for growth as the prevalence of respiratory diseases such as asthma, COPD in emerging economies such as India and China. In addition, increasing the geriatric population specially in Japan is another major reason for the growth of the market.
To Request a Sample of our Report on Asia-Pacific Dry Powdered Inhaler Market: https://www.omrglobal.com/request-sample/asia-pacific-dry-powdered-inhaler-market
Asia-Pacific dry powdered inhaler market is segmented based on type, application, and end-user. Based on the type, preventive, reliever, and long-acting bronchodilators dry powdered inhalers are analyzed. The preventive dry powdered inhaler segment led the global dry powdered inhaler market in 2018. Preventive inhalers are most widely used in the treatment of asthma in children and adults. These inhalers do not entail side effects for long-term use, and exceptionally decreases the possibility of an asthma exacerbation. The preventive inhalers further reduce the airways swelling and hence, are recommended for regular use by the physician. Some of the preventive inhalers available in the market include Budesonide and Fluticasone. Moreover, based on the application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
(Get 15% Discount on Buying this Report)
A full Report of Asia-Pacific Dry Powdered Inhaler Market is Available @ https://www.omrglobal.com/industry-reports/asia-pacific-dry-powdered-inhaler-market
Asia-Pacific Dry Powdered Inhaler Market Segmentation
By Type
- Preventive Inhaler
- Reliever Inhaler
- Long Acting Bronchodilators Inhaler
By Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
By End-User
- Homecare
- Hospitals and Clinics
Regional Analysis
- China
- Japan
- India
Rest of Asia-Pacific
Company Profiles
- 3M Co.
- Acorda Therapeutics, Inc.
- Adamis Pharmaceuticals Corp.
- Adherium Ltd.
- Aradigm Corp.
- AstraZeneca PLC
- Beximo Pharmaceuticals Ltd.
- Boehringer Ingelheim International GmbH
- Cipla Ltd.
- GlaxoSmithKline PLC
- Koninklijke Philips N.V.
- MidasCare Pharmaceutical Pvt. Ltd.
- Novartis AG
- Omron Healthcare Inc.
- ResMed Corp.
- Sunovion Pharmaceuticals
- Teijin Pharma Ltd.
- Teva Pharmaceuticals Industries Ltd.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
